Navigation Links
Egalet Announces Financing to Fund Abuse-Deterrent Medications
Date:9/12/2013

MALVERN, Pa., Sept. 12, 2013 /PRNewswire/ -- Egalet Ltd., a specialty pharmaceutical company developing and planning to commercialize abuse-deterrent oral products for the treatment of pain and other indications, announced today that it has closed a financing of up to $20 million led by Index Ventures with participation from other existing investors.  Egalet has received $10 million initially, with an option for an additional $10 million investment under pre-specified conditions.

Prescription drug abuse became the leading cause of accidental death in the United States in 2008 surpassing deaths caused by automobile accidents.  A 2011 research report prepared by the Substance Abuse and Mental Health Services Administration of the U.S. Department of Health and Human Services, or SAMHSA, estimated that nearly 35 million Americans have used prescription pain relievers, including opioid-containing drugs, for non-prescription purposes at least once in their lifetime.  As of 2007, the total costs of prescription drug abuse were estimated to be up to $72.5 billion annually for public and private healthcare payors in the United States according to the North American Journal of Managed Care. 

Egalet has created two distinct drug delivery systems, each with novel abuse-deterrent features and the ability to control the release profile of the active pharmaceutical ingredient, or API. Using the Company's proprietary platform, Egalet has developed a pipeline of clinical-stage, opioid-based product candidates in tablet form that are specifically designed to deter abuse by physical and chemical tampering while also providing tailored release of the API.  Egalet's lead product candidates, Egalet-001 and Egalet 002, are abuse-deterrent, extended-release, oral formulations of commonly prescribed opioids in development for the treatment of moderate to severe pain.  Egalet-001 and Egalet 002, if approved, could fill significant unmet needs in the marketplace.

"With these funds we will be able to begin our pivotal studies for Egalet 001 in the first quarter of 2014," said Bob Radie, Egalet's president and chief executive officer.  "We plan to submit a new drug application, or NDA, to the U.S. Food and Drug Administration, or FDA, in the fourth quarter of 2014."

About Egalet Ltd.

Egalet Ltd. is a specialty pharmaceutical company developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and other indications.  The company has created two distinct drug delivery systems, each with novel abuse-deterrent features and the ability to control the release profile of the active pharmaceutical ingredient.  Using its proprietary platform, Egalet  has developed a pipeline of clinical-stage, opioid-based product candidates in tablet form that are specifically designed to deter abuse by physical and chemical tampering while also providing tailored release of the active pharmaceutical ingredient.  The Egalet technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple APIs with similar or different release profiles.   The company's goal is to be a leading specialty pharmaceutical company focused on the development, manufacture and commercialization of abuse-deterrent pharmaceutical products.  Please visit www.egalet.com for more information.

Contact:
E. Blair Clark-Schoeb
Tel.: 917-432-9275
Email: blair@biotechcomm.com


'/>"/>
SOURCE Egalet Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Egalet to Present at Life Sciences Europe Conference
2. Egalet Announces Issuance of U.S. Patent
3. CLAAD Selects Egalet As Top Five Technologies To Reduce Prescription Drug Abuse Honoree
4. Egalet Appoints Stan Musial as CFO
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Research and Markets has announced the addition of the ... their offering. ... The interventional radiology products market is expected to reach USD 8.02 ... CAGR of 4.8%. This market is segmented based on type, procedure, ... of this market are rising incidence of chronic diseases, rising geriatric ...
(Date:1/23/2017)... , Jan. 23, 2017 LifeVac, the ... a blocked airway and prevented choking deaths, welcomes ... advocate to the LifeVac team as Official Spokesperson. ... join the LifeVac team," said Arthur Lih , ... to represent LifeVac and his mission to raise awareness ...
(Date:1/23/2017)... TORONTO , Jan. 23, 2017 ... both 510(k) clearance from the U.S. Food and ... from Health Canada enabling the North American commercial ... (MIGS™) system for spine surgery, the 7D Surgical ... employs cutting-edge 3D optical technologies and machine vision ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... The Masters of Science in ... leaders with decades of experience who remain current practitioners in the field. With ... there is a renewed demand for versatile, data-driven leadership.The American University’s MS in ...
(Date:1/23/2017)... , ... January 23, 2017 , ... ... on Crystallization in Process Chemistry by Applying Simple PAT Tools . , ... compounds to isolate and purify the desired product. Chemists now spend more ...
(Date:1/23/2017)... ... 23, 2017 , ... Old School Labs™, makers of the wildly popular all-natural ... Breon Ansley to its growing team of brand ambassadors. The Olympia top finisher and ... less than a year was able to turn professional, participating in the 2013 NPC ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Crossing the Bar”: a moving and eloquent ... life. “Crossing the Bar” is the creation of published author, Charlotte Hotte, a North ... who credits the inspiration of the book to her sister, Denise, wishes to acknowledge ...
(Date:1/23/2017)... ... 23, 2017 , ... Valentine’s Day is a time when many people celebrate romance and love ... may be looking for the ideal present, Atlanta-based Perimeter Plastic Surgery is offering ... free. Or, spend $200 and get $50 free. , “A lot of people just ...
Breaking Medicine News(10 mins):